INTRODUCTION
Primary biliary cholangitis (PBC) is a chronic cholestatic l ive r c ond it i on af fe c t i ng predominantly middle-aged women. It may exert a significant negative effect on the patient`s health-related quality of life (HRQoL) manifesting itself with intense pruritus and chronic fatigue in a substantial proportion of patients [1] . Ursodeoxycholic acid (UDCA) remains a standard therapy for PBC. However, a significant proportion of patients do not respond to this treatment [2] . S-adenosyl-L-methionine (SAMe) is involved in numerous biochemical reactions, playing a role of a major methyl and sulfate group donor and a precursor of cysteine and glutathione [3] . Chronic liver disease induces an acquired deficiency of methionine adenosyltransferase, which catalyzes SAMe formation from methionine leading to a depletion of the amount of SAMe and potential impairment of detoxifying processes in the liver [3] . SAMe as a single agent has been used in the past for the treatment of chronic liver diseases with equivocal results [4, 5] . Our previous experimental works demonstrated that simultaneous treatment with UDCA J Gastrointestin Liver Dis, September 2018 Vol. 27 No 3: [273] [274] [275] [276] [277] [278] [279] and SAMe may exert beneficial, additive effect ameliorating cholestasis [6] . We postulated that hepatoprotective effects of SAMe may result from its role as a precursor of sulfate groups for detoxification processes in the liver [7, 8] .
In this prospective, pilot, proof of the principle and open label study we analyzed the effect of the simultaneous treatment of UDCA and SAMe on liver biochemistry and HRQoL in patients with PBC.
MATERIAL AND METHODS
We prospectively enrolled 24 consecutive patients with PBC, all female, treated with UDCA in a standard dose over a period of at least 6 months. All patients were recruited at two Polish Universities (Medical University of Warsaw, Warsaw and Pomeranian Medical University, Szczecin) between October 2015 and October 2016. The diagnosis of PBC was established according to the European Association for the Study of Liver criteria [2] . The severity of liver fibrosis was estimated by Shear Wave Elastography (SuperSonic Imagine; Aixplorer, Aix-en-Provence, France) performed by a single, experienced professional. A cut-off value for the diagnosis of liver cirrhosis was set at 13.0 kPa according to a recent metaanalysis [9] . Patients with concomitant liver diseases, taking immunosuppressive, antipruritic, antihyperlipidemic and antidepressive drugs three months prior to baseline recording were considered not suitable for the study. Beside UDCA in the dose of 13-15 mg/kg b.w., all patients received vitamin D and calcium supplementation.
Participants received SAMe 1200 mg/daily in two divided doses (800 mg in the morning and 400 mg midday) over the period of 6 months. In both study centres they were monitored by experienced hepatologists in out-patient clinics at baseline, interim visits at weeks: 2, 4, 12, end of treatment at 24 weeks and follow-up visit after 4-6 weeks wash-out period. Treatment and intervention adherence, adverse events, serum biochemistry and HRQoL were assessed at each visit.
Laboratory assessments encompassed routine serum biochemistry including alanine (ALT) and aspartate aminotransferases (AST), gammaglutamyl-transpeptidase (GGT), alkaline phosphatase (ALP), total bilirubin, albumin, international normalized ratio (INR) and total cholesterol.
In order to investigate the effect of SAMe on liver sulfation capacities, serum levels of lithocholic acid (LCA) and sulfated LCA (LCA-S) were measured using validated liquid chromatography/tandem mass spectrometry (LC-MS/ MS) method [10, 11] . For each patient, LCA/LCA-S ratio was subsequently calculated.
As we previously showed, fibroblast growth factor-19 (FGF-19), an important regulatory factor of bile acids synthesis, may serve as a valuable indicator of the cholestatic liver injury [12] . Therefore, in order to evaluate the potential hepatoprotective role of SAMe in cholestasis, we measured FGF-19 serum levels in the study group at the baseline and end-point as we described before [12] .
HRQoL was assessed with a disease-specific questionnaire (PBC-40) [13, 14] . Chronic fatigue was measured by Modified Fatigue Impact Scale (MFIS) [15] . Emotional distress was assessed with Hospital Anxiety and Depression Scale (HADS) [16] and State-Trait Anxiety Inventory (STAI).
Four patients dropped-out from the study (one patient 2 weeks after inclusion, three others 4 weeks after inclusion) due to non-specific symptoms including abdominal pain or cramps. As the study protocol did not permit antipruritic therapies two other patients who complained of significant itching at baseline and who did not notice any improvement during the treatment were also removed from the study (at 4 weeks) in order to implement antipruritic therapy. Thus, 18 patients (10 with cirrhosis) aged 38-65 years (mean 54.2±8.2) were finally included.
Twenty four age-matched, consecutive female patients with PBC treated with UDCA for a period of at least 6 months served as controls for a comparison of liver biochemistry. 
Ethics

Statistical analysis
Descriptive statistical methods were used to analyze all variables. Continuous variables were evaluated using the number of observations, arithmetic mean and standard deviation (SD). Categorical data are described using absolute frequencies. To evaluate the changes in serum liver function tests we calculated delta values from baseline to the end of treatment visit for each patient. The Shapiro-Wilk normality test was used to examine the distribution of quantitative variables. The Wilcoxon matched-pairs signed rank test and the paired t-test were applied as appropriate to calculate the differences between variables at single time points. Pearson correlation coefficients and chi-square test were used to check the variables influencing SAMe biochemical response. To compare the differences between study and control groups unpaired t-test or Mann-Whitney test were applied. Calculations were performed using GraphPad Prism for Windows (Version 7.0). A p value less than 0.05 was considered statistically significant.
RESULTS
The baseline demographic and liver biochemistry data of study and control group are presented in Table I . At the enrolment there were no significant differences between the study and the control group.
Effect of SAMe on liver biochemistry
When baseline and 6 months results were compared, a significant improvement in ALP, GGT and cholesterol levels was seen in non-cirrhotic patients treated with SAMe. These data are shown in Fig. 1 . In patients with cirrhosis, a significant J Gastrointestin Liver Dis, September 2018 Vol. 27 No 3: 273-279 reduction of bilirubin level was noted. When all patients treated with SAMe were considered there was a significant reduction of total bilirubin and GGT levels. In the control group there were no changes in liver function tests. Data on liver biochemistry in all analysed groups are summarized in Table II . Withdrawal of SAMe caused almost uniform increase of liver biochemistry taken one month later but it did not reach statistical significance (Supplementary Fig. 1 ).
Effect of SAMe on sulfation of LCA and FGF-19 levels
Serum LCA and LCA-S concentrations were used to estimate the sulfation capacity of the liver (LCA/LCA-S ratio). Data presented as the arithmetic means ± SD. At the baseline demographic data and liver biochemistry were comparable in the study and in the control groups.
Fig. 1. Serum ALP (A)
, GGT (C) and total cholesterol (E) levels throughout the study period in non-cirrhotic and cirrhotic patients treated with SAMe. In non-cirrhotic patients serum ALP, GGT and total cholesterol levels decreased after 24 weeks of SAMe treatment. Absolute changes in serum ALP (B), GGT (D) and total cholesterol (F) levels throughout the study period in non-cirrhotic and cirrhotic patients treated with SAMe. In non-cirrhotic patients mean absolute changes in GGT and cholesterol levels were significantly higher than in cirrhotic patients. Y axis indicates absolute changes compared to baseline levels. Continuous variables are summarized using the arithmetic mean and the standard error of the mean (SEM 
Effect of SAMe on the HRQoL
In line with the enhancement of markers of liver injury the therapy with SAMe led to the improvement of the patients' well-being. In particular, a significant improvement of fatigue and pruritus measured by PBC-40 questionnaire as well as emotional distress in STAI 2 was seen when scorings from baseline and end of treatment were compared. There was also a trend towards the improvement of MFIS scores and Depression and Anxiety domains of HADS without reaching statistical significance. These data are summarized in Table III .
DISCUSSION
SAMe plays a crucial role in several biochemical processes exerting its protective effect in various cells. Several conditions that increase oxidative stress, hypoxia or nitric oxide synthesis, which include viral hepatitis, alcoholic liver disease or various toxins disturb synthesis of SAMe via a direct effect on methionine adenyltransferase, i.e. the enzyme responsible for SAMe synthesis from methionine [17] . We have recently shown that protection against oxidative stress mediated by Nrf2/Keap1 pathway is also significantly impaired in PBC [18] .
SAMe has been extensively studied in a large number of animal and experimental studies. Its supplementation leads to increased intracellular concentration of glutathione both in experimental models [19] and in patients with liver diseases [20] . It prevented liver hypoxia and restored activity of mitochondrial respiratory complexes in a rat model of alcohol induced fatty liver [21] .
In terms of using SAMe in humans, literature data are scanty. A recent meta-analysis screened almost 2000 articles (both animal and human studies) selecting only 11 studies as being suitable for the analysis [22] . Strikingly, in all but two was well tolerated and no severe adverse effects were reported. The second longest trial mentioned in the meta-analysis was a randomized, double blind study undertaken by Medici et al. [5] . It comprised 37 subjects with alcoholic liver disease, 18 of them received SAMe and 19 placebo. The SAMe dose of 1200 mg/daily was identical to the one used in the Mato et al. [4] study and it was administered over the period of 6 months. An improvement of liver biochemistry in both groups was seen, likely related to alcohol abstinence, and it was not significantly better in SAMe group than in the placebo one. This perhaps should not be a surprise when we compared these results with the study of Mato et al. [4] on patients with the same etiology, where no effect was seen after 6 months of SAMe treatment. Indeed, Medici et al. [5] study seems to confirm the notion that SAMe ideally should be used for a longer period of time, at least in patients with alcoholic etiology. This concept may somehow be supported by the results of the study by Feld et al. [23] . They clearly demonstrated that adding SAMe in the dose of 800mg bd to the treatment of hepatitis C with pegylated interferon and ribavirin over a period of 12 months increased interferon stimulated gene in non-responders to previous therapy. The in vitro work included in this study [23] showed that SAMe improved interferon signalling and its antiviral effect. This phenomenon was linked to enhanced metylation induced by SAMe. As there is only one published randomized study where SAMe was used as a single agent for a period longer than 6 months, one has to agree with the conclusion of the review paper which said that "to date no large, high quality, randomized placebo-controlled clinical trials have been performed that definitely establish clinical utility (of SAMe) in specific disease states" [24] . In this pilot, proof of the principle and open label work we studied the effect of SAMe on liver biochemistry and HRQoL in a small group of consecutive patients with PBC who were treated with UDCA for a period of at least 6 months. A rationale for this analysis was based on our laboratory studies performed almost two decades ago when we used a hepatocyte couplets model for the study of hepatoprotection in experimentally induced cholestasis [6, 7, 25, 26] . We demonstrated both protective and reversing effect of SAMe on lithocholate and 17β-estradiol glucuronide induced cholestasis. This effect was additive in the former when UDCA and SAMe were used simultaneously. As UDCA and SAMe exert their hepatoprotective effects by different molecular and biochemical mechanisms, it is conceivable that when used together, their effect may potentially be additive. We have shown that the hepatoprotective effect of SAMe, at least partially and in experimental models, may be related to its role as a sulphate donor, as the anticholestatic effect of SAMe was ameliorated by dehydroepiandrosterone, which competes for sulphate group with 17β-estradiol glucuronide. Sulphation of the latter makes it more water soluble and non-cholestatic.
These present results did not, however, confirm our hypothesis on a potential role of SAMe as a sulphate donor. Although we observed an enhancement of sulphated derivative of LCA in both cirrhotic and non-cirrhotic patients treated with SAMe, these changes did not reach statistical significance. Treatment with SAMe had also no effect on serum levels of FGF-19, which as we demonstrated before, correlate with Mayo Risk Score and are significantly increased in UDCA non-responders [12] . These findings may be related to the small size of the analysed cohort and, in our opinion, require further studies on a larger group of patients.
In the present study we observed a significant improvement in ALP, GGT and total cholesterol in non-cirrhotic patients. This may suggest that SAMe exerts its effect particularly in earlier stages of the disease and it may somehow correspond with the results of the Mato et al. [4] study where SAMe showed no effect in patients with advanced disease and the Child C score.
HRQoL has emerged as one of the most important issues in contemporary medicine. Improvement in liver biochemistry excites treating physicians, but from the patients' perspective does not mean much if it is not associated with improved QoL. Some treatments may clearly improve the liver tests but simultaneously have no effect or even affect negatively patients' wellbeing, a good example being steroids in autoimmune hepatitis. Chronic fatigue and pruritus are considered to be the most debilitating symptoms in PBC. Treatment with SAMe caused a significant improvement of both symptoms. Certainly, these results have to be interpreted with caution. First of all, patients included into the study did not have a significant itching and did not use antipruritic agents over the period of study. Two patients with more pronounced itching were withdrawn within one month as they did not observe any improvement of their pruritus and were put on antipruritic treatment. Thus, a statistically significant improvement of pruritus is a surprise, but on the other hand a positive effect of SAMe on itching was reported in a randomized study in obstetric cholestasis [27] . We have also seen a significant improvement caused by SAMe on the fatigue domain of PBC-40 questionnaire. SAMe has a well described antidepressive properties, which are comparable to selective serotonin reuptake inhibitors (SSRIs) [28] . Although SSRIs did not prove effective in the treatment of fatigue in PBC in a small randomized study [29] , antidepressants are frequently prescribed in fatigued patients with PBC [30] . A recent review strongly suggested that SAMe might prove useful in various psychiatric conditions including not only depression but also mood disturbance or anxiety [31] . In our patients treated with SAMe we observed a significant improvement in the STAI 2 questionnaire, which is a well validated tool for the assessment of anxiety. We have also seen a trend towards improvement in the Modified Fatigue Impact Scale and Depression and Anxiety domain of HADS but certainly it is too early to draw any firm conclusions from these findings. Four patients were removed from the study because of unspecific symptoms, mostly abdominal cramps. As SAMe in the dose we used or 800 mg bd was well tolerated in other studies, this finding was indeed unexpected. The severity of symptoms was mild/moderate and perhaps not related to the treatment (one third of the patients with PBC report unspecific right upper abdominal quadrant pain); however, we decided to remove these patients from the study after 4 weeks.
CONCLUSIONS
In this pilot study on a small cohort of patients with PBC we observed a significant improvement of liver biochemistry J Gastrointestin Liver Dis, September 2018 Vol. 27 No 3: 273-279 caused by SAMe in non-cirrhotics and a clear positive effect on HRQoL. In our opinion, these early results warrant further study on a larger cohort of patients to characterize a potential positive effect of SAMe in patients with chronic cholestatic liver conditions.
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